Listing of Claims:

1. (currently amended): A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ~~i~~, ii, ~~iii, or iv~~



ii

B is

(a)  ,

(b)  , or

(c)  ;

W is $NHC(=X)R_1$, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection (b);

Y is NH, O, or S;

Z is $S(=O)(=N\text{-}R_5)$;

R_1 is

(a) H,

(b) NH_2,

(c) $NHC_{1\text{-}4}$alkyl,

(d) C_{1-4}alkyl,

(e) C_{2-4}alkenyl,

(f) OC_{1-4}alkyl,

(g) SC_{1-4}alkyl, or

(h) $(CH_2)_p C_{3-6}$cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R_1 is optionally substituted with one or more F, Cl or CN;

R_2 and R_3 are independently H, F, Cl, methyl or ethyl;

R_4 is H, CH_3, or F;

R_5 is

(c) $C(=O)C_{1-4}$alkyl,

(d) $C(=O)OC_{1-4}$alkyl,

(e) $C(=O)NHR_6$, or

(f) $C(=S)NHR_6$;

R_6 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, alkyl in R_5 and R_6 is optionally substituted with one or more halo, CN, NO_2, phenyl, C_{3-6} cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, NR_7R_7, oxo, or oxime;

R_7 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, ~~CF_3, CH_3~~, CN, NO_2, phenyl, C_{3-6} cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7; **when R_5 is C_{1-4}alkyl substituted with phenyl, the phenyl is additionally optionally substituted with CF_3 and CH_3;**

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2; and

n is 2 or 3.

2. (previously amended): A compound of claim 1 having the formula IA:



IA.

3. (original): A compound of claim 2 wherein R_1 is C_{1-4}alkyl.

4. (original): A compound of claim 2 wherein R_1 is ethyl.

5. (original): A compound of claim 2 wherein R_1 is methyl.

6. (original): A compound of claim 2 wherein R_1 is C_{3-6}cycloalkyl.

7. (original): A compound of claim 2 wherein R_1 is cyclopropyl.

8. (previously amended): A compound of claim 2, 3, 4, 5, 6, or 7 ~~2-7~~ wherein X is a sulfur atom.

9. (previously amended): A compound of claim 2, 3, 4, 5, 6, or 7 ~~2-7~~ wherein X is an oxygen atom.

10. (original): A compound of claim 8 wherein one of R_2 and R_3 is H, the other one is F.

11. (original): A compound of claim 9 wherein one of R_2 and R_3 is H, the other one is F.

12. (original): A compound of claim 8 wherein R_4 is H.

13. (original): A compound of claim 9 wherein R_4 is H.

14. (original): A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

15. (canceled).

16. (previously amended): A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

17. (original): A compound of claim 9 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

18-21. (canceled).

22. (original): A compound of claim 14 wherein R_5 is $C(=O)C_{1-4}$alkyl, $C(=O)OC_{1-4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1-4}$alkyl.

23. (original): A compound of claim 22 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

24. (original): A compound of claim 14 wherein R_5 is $C(=O)CH_3$.

25. (original): A compound of claim 14 wherein R_5 is $C(=O)OCH_3$.

26-29. (canceled).

30. (original): A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula I as shown in claim 1.

31. (original): The method of claim 30 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

32. (original): The method of claim 30 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

33. (original): The method of claim 30 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

34. (original): A method for treating microbial infections of claim 30 wherein the infection is skin infection.

35. (original): A method for treating microbial infections of claim 30 wherein the infection is eye infection.

36. (original): A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

37. (canceled).

38. (original): A compound of claim 16 wherein R_5 is $C(=O)C_{1-4}$alkyl, $C(=O)OC_{1-4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1-4}$alkyl.

39. (original): A compound of claim 38 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

40. (original): A compound of claim 16 wherein R_5 is $C(=O)CH_3$.

41. (original): A compound of claim 16 wherein R_5 is $C(=O)OCH_3$.

42. (original): A compound of claim 17 wherein R_5 is $C(=O)C_{1-4}$alkyl, $C(=O)OC_{1-4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1-4}$alkyl.

43. (original): A compound of claim 42 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

44. (original): A compound of claim 17 wherein R_5 is $C(=O)CH_3$.

45. (original): A compound of claim 17 wherein R_5 is $C(=O)OCH_3$.

46. (currently amended): A compound of claim 2 which is

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{[(methylamino)carbonyl]imino}-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

~~N-({(5*S*)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;~~

N-({(5*S*)-3-[3-fluoro-4-(1-{[[(4-nitrophenyl)amino]carbonyl]imino}-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer ;

N-({(5*S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

~~N-({(5*S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;~~

N-[((5*S*)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1λ^4, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanethioamide;

N-[((5*S*)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1λ^4, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide ;

N-[((5*S*)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5- yl)methyl] cyclopropanecarbothioamide, *Z*-isomer;

N-[((5*S*)-3-{3-fluoro-4-[1-[[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, *Z*-isomer; or

N-({(5*S*)-3-[3-fluoro-4-(1-{[(benzylamino)carbonyl]imino}-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer.

47. (currently amended). ~~1.~~ A compound of formula II



II

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii



ii ;

B is



;

W is NHC(=X)R_1, or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is S(=O)(=N-R_5) and the B ring has the following stereochemistry





;



;

R_1 is

(a) H,

(b) NH_2,

(c) NHC_{1-4}alkyl,

(d) C_{1-4}alkyl,

(e) C_{2-4}alkenyl,

(f) OC_{1-4}alkyl,

(g) SC_{1-4}alkyl, or

(h) $(CH_2)_p C_{3-6}$cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R_1 is optionally substituted with one or more F, Cl or CN;

R_2 and R_3 are independently H, F, Cl, methyl or ethyl;

R_4 is H, CH_3, or F;

R_5 is

(a) H,

(b) C_{1-4}alkyl,

(c) $C(=O)C_{1-4}$alkyl,

(d) $C(=O)OC_{1-4}$alkyl,

(e) $C(=O)NHR_6$, or

(f) $C(=S)NHR_6$;

R_6 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, alkyl in R_5 and R_6 is optionally substituted with one or more halo, CN, NO_2, phenyl, C_{3-6} cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, NR_7R_7, oxo, or oxime;

R_7 is H, C_{1-4}alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CN, NO_2, phenyl, C_{3-6} cycloalkyl, OR_7, $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7; **when R_5 is C_{1-4}alkyl substituted with phenyl, the phenyl is additionally optionally substituted with CF_3 and CH_3;**

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2;

~~and ===== in structure iii is either a double bond or a single bond~~.

48. (previously presented): The compound of claim 47 wherein R_1 is C_{1-4}alkyl.

49. (previously presented): The compound of claim 47 wherein R_1 is ethyl.

50. (previously presented): The compound of claim 47 wherein R_1 is methyl.

51. (previously presented): The compound of claim 47 wherein R_1 is C_{3-6}cycloalkyl.

52. (previously presented): The compound of claim 47 wherein R_1 is cyclopropyl.

53. (previously presented): The compound of claim 47 wherein X is a sulfur atom.

54. (previously presented): The compound of claim 47 wherein X is an oxygen atom.

55. (previously presented): The compound of claim 53 wherein one of R_2 and R_3 is H, the other one is F.

56. (previously presented): The compound of claim 54 wherein one of R_2 and R_3 is H, the other one is F.

57. (previously presented): The compound of claim 47 wherein R_5 is H.

58. (previously presented): The compound of claim 47 wherein R_5 is C_{1-4}alkyl, optionally substituted with OH; or C_{1-4}alkyl substituted with $C(=O)NHC_{1-4}$alkyl, $C(=O)NH_2$ or phenyl; wherein the phenyl is optionally substituted with OH, methyl, NO_2, CF_3, or CN.

59. (previously presented): The compound of claim 47 wherein R_5 is CH_3, or ethyl.

60. (previously presented): The compound of claim 47 wherein R_5 is C_{1-4}alkyl substituted with phenyl wherein the phenyl is optionally substituted with NO_2.

61. (previously presented): The compound of claim 47 wherein R_5 is $C(=O)C_{1-4}$alkyl, $C(=O)OC_{1-4}$alkyl, $C(=O)NH_2$, or $C(=O)NHC_{1-4}$alkyl.

62. (previously presented): The compound of claim 47 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

63. (previously presented): The compound of claim 47 wherein R_5 is $C(=O)CH_3$.

64. (previously presented): The compound of claim 47 wherein R_5 is $C(=O)OCH_3$.

65. (previously presented): A compound of claim 47 which is N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{[(methylamino)carbonyl]imino}-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{[[(4-nitrophenyl)amino]carbonyl]imino}-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer ;

N-({(5*S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;
N-({(5*S*)-3-[3-fluoro-4-[1-[(2-hydroxyethyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;
N-({(5*S*)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanecarbothioamide, *Z*-isomer;
N-[((5*S*)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide, *Z*-isomer;
N-[((5*S*)-3-{3-fluoro-4-[1-[[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, *Z*-isomer; or
N-({(5*S*)-3-[3-fluoro-4-(1-{[(benzylamino)carbonyl]imino}-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer.

66. (previously presented): A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula II as shown in claim 47.

67. (new) A compound selected from the group consisting of N-({(5*S*)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;
N-({(5*S*)-3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-1λ^4-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer.

Applicant respectfully requests re-consideration and allowance of these amended and newly presented claims.

Respectfully submitted,

John H. Engelmann

Date: JUNE 24, 2004

John H. Engelmann, Attorney
Registration No. 28,075

Pharmacia & Upjohn Company
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-1837 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316